The Association between Metformin and the Cancer-Specific Mortality Rate in Nasopharyngeal Cancer Patients: Real-World Evidence.

Published in: Current oncology (Toronto, Ont.) (2023)

We concluded that Metformin might be effective at reducing the cancer-specific mortality rate in nasopharyngeal cancer patients. Further randomized control trials should be completed.

Keyphrases

papillary thyroid
cardiovascular events
squamous cell
double blind
risk factors
clinical trial
open label
randomized controlled trial
phase iii
squamous cell carcinoma
phase ii
respiratory tract